Page last updated: 2024-10-26

felbamate and Aura

felbamate has been researched along with Aura in 142 studies

Felbamate: A PEGylated phenylcarbamate derivative that acts as an antagonist of NMDA RECEPTORS. It is used as an anticonvulsant, primarily for the treatment of SEIZURES in severe refractory EPILEPSY.
felbamate : The bis(carbamate ester) of 2-phenylpropane-1,3-diol. An anticonvulsant, it is used in the treatment of epilepsy.

Research Excerpts

ExcerptRelevanceReference
"We studied the efficacy of felbamate (FBM) in combination with valproic acid (VPA) in 13 patients with the Lennox-Gastaut syndrome and evaluated the contribution of each drug."9.09The efficacy of felbamate as add-on therapy to valproic acid in the Lennox-Gastaut syndrome. ( Flamini, R; Gaillard, WD; Kelley, K; Ko, D; Malow, B; Reeves-Tyer, P; Siegel, H; Stertz, B; Theodore, WH, 1999)
"The objective of this study was to assess the psychiatric effects of the antiepileptic drug (AED) felbamate (FBM) in patients with epilepsy."9.08Felbamate monotherapy has stimulant-like effects in patients with epilepsy. ( Flamini, R; Ketter, TA; Ko, D; Malow, BA; Post, RM; Theodore, WH; White, SR, 1996)
"Felbamate (FBM, Felbatol/Taloxa), a new antiepileptic drug (AED), was tested in a placebo-controlled add-on design in 73 patients with therapy refractory Lennox-Gastaut syndrome."9.07Felbamate in the treatment of Lennox-Gastaut syndrome. ( Jensen, PK, 1994)
"Our patient's electrographic status epilepticus of sleep resolved after treatment with felbamate."7.81Successful Treatment of Electrographic Status Epilepticus of Sleep With Felbamate in a Patient With SLC9A6 Mutation. ( Coorg, R; Weisenberg, JL, 2015)
"To present our experience with felbamate therapy in children with drug-resistant epilepsy."7.80Efficacy and safety of felbamate in children with refractory epilepsy. ( Epstein, O; Gandelman-Marton, R; Heyman, E; Lahat, E; Levin, N, 2014)
"The antiepileptic drug felbamate has demonstrated efficacy against a variety of seizure types in the pediatric population, particularly seizures associated with Lennox-Gastaut syndrome."7.76Efficacy of felbamate in the treatment of intractable pediatric epilepsy. ( Chico, MS; Eggener, KA; Hecox, KE; Marcuccilli, CJ; O'Connor, SE; Roell Werner, R; Schwabe, MS; Zupanc, ML, 2010)
"We present an implementation of a method we previously reported allowing the newer antiepileptic drugs (AEDs) rufinamide (RFN) and zonisamide (ZNS) to be simultaneously determined with lamotrigine (LTG), oxcarbazepine's (OXC) main active metabolite monohydroxycarbamazepine (MHD) and felbamate (FBM) in plasma of patients with epilepsy using high performance liquid chromatography (HPLC) with UV detection."7.76Simultaneous HPLC-UV analysis of rufinamide, zonisamide, lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in deproteinized plasma of patients with epilepsy. ( Albani, F; Baruzzi, A; Candela, C; Contin, M; Mohamed, S; Riva, R, 2010)
"A very simple and fast method has been developed and validated for simultaneous determination of the new generation antiepileptic drugs (AEDs) lamotrigine (LTG), oxcarbazepine's (OXC) main active metabolite monohydroxycarbamazepine and felbamate in plasma of patients with epilepsy using high-performance liquid chromatography (HPLC) with spectrophotometric detection."7.73Simultaneous liquid chromatographic determination of lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in plasma of patients with epilepsy. ( Albani, F; Balboni, M; Baruzzi, A; Callegati, E; Candela, C; Contin, M; Riva, R, 2005)
"The aim of the study was to assess the efficacy and safety of felbamate (FBM) as add-on therapy in pediatric patients with severe uncontrolled seizures during a 3-year follow-up."7.71The long-term use of felbamate in children with severe refractory epilepsy. ( Cilio, MR; Kartashov, AI; Vigevano, F, 2001)
"Influence Felbamate on the cerebral bioelectric activity (EEG) in the group of 31 children (18 with syndrome Lennox-Gastaut, 13 with partial epilepsy) with refractory epilepsy was investigated."7.70[Preliminary assessment of felbamate effect on the cerebral bioelectrical activity in children with refractory epilepsy]. ( Kuszczak, B; Mazur, J; Pakszys, M; Rusek, G; Szamotulska, K, 2000)
"The behavioral effects of felbamate were assessed in 20 persons, (ages 2 to 19 years) who were participating in a compassionate plea protocol for children with Lennox-Gastaut syndrome."7.69Behavioral effects of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). ( Coskey, JS; Gay, PE; Mecham, GF; Sadler, T; Thompson, JA, 1995)
"We prospectively investigated drug-induced headaches (HA) among 60 epileptic patients receiving felbamate (FBM)."7.69Felbamate-induced headache. ( Andriola, MR; Berdia, A; Ettinger, AB; Jandorf, L; Krupp, LB; Weisbrot, DM, 1996)
"The usefulness of felbamate (FBM) levels in managing epilepsy patients has not been determined."7.69Felbamate levels in patients with epilepsy. ( Harden, CL; Kutt, H; Trifiletti, R, 1996)
"Felbamate was compared with several antiepileptic drugs for protective effects in two rat models of status epilepticus."7.68Effects of felbamate and other anticonvulsant drugs in two models of status epilepticus in the rat. ( Diamantis, W; Gels, M; Gordon, R; Sofia, RD, 1993)
"Felbamate (FBM) pharmacokinetic parameters, safety and tolerability in the dose range of 1,200-6,000 mg/day were assessed in two open-label studies with similar designs."6.68Tolerability and pharmacokinetics of monotherapy felbamate doses of 1,200-6,000 mg/day in subjects with epilepsy. ( Lyness, WH; Narang-Sachdeo, SK; Perhach, JL; Rosenberg, A; Sachdeo, R; Shumaker, RC, 1997)
"felbamate appears to be an effective new AED: the most adverse effects occurring during administration of FBM are mild to moderate gastrointestinal (nausea, vomiting and anorexia) and central nervous system (headache, sonnolence, diplopia, dizziness and insomnia) disturbances."6.68[Felbamate: a long-term study in subjects with refractory epilepsy]. ( De Romanis, F; Sopranzi, N, 1997)
"Felbamate was licensed in 1993 for use as adjunctive therapy or monotherapy in adults with partial or tonic-clonic seizures and as adjunctive therapy for children with the Lennox-Gastaut syndrome."6.39Guidelines for treating epilepsy in the age of felbamate, vigabatrin, lamotrigine, and gabapentin. ( Laxer, KD, 1994)
"Felbamate (FBM) is an effective and safe novel antiepileptic drug (AED) for add-on treatment in adults with refractory partial seizures as shown in three pivotal controlled trials."6.38Felbamate: successful development of a new compound for the treatment of epilepsy. ( Schmidt, D, 1993)
"9%) seizure frequency was reduced by more than 50% (mean FBM dosage 3211 mg), and 13 patients (31."5.34[Treatment of epilepsy with third-line antiepileptic drugs: felbamate, tiagabine, and sulthiame]. ( Bauer, J; Chahem, J, 2007)
"The patient experienced complete seizure control and almost complete return of language skills following the addition of felbamate."5.29Felbamate in the treatment of acquired epileptic aphasia. ( Glauser, TA; Olberding, LS; Piccirillo, DM; Titanic, MK, 1995)
"Pretreatment with felbamate at either dose prevented the progression of rank of seizures during chronic treatment with PTZ."5.29Anticonvulsant effect of felbamate in the pentylenetetrazole kindling model of epilepsy in the rat. ( Carboni, G; Corda, MG; Feldman, A; Frau, V; Giorgi, O; Orlandi, M; Valentini, V, 1996)
"We studied the efficacy of felbamate (FBM) in combination with valproic acid (VPA) in 13 patients with the Lennox-Gastaut syndrome and evaluated the contribution of each drug."5.09The efficacy of felbamate as add-on therapy to valproic acid in the Lennox-Gastaut syndrome. ( Flamini, R; Gaillard, WD; Kelley, K; Ko, D; Malow, B; Reeves-Tyer, P; Siegel, H; Stertz, B; Theodore, WH, 1999)
"Felbamate is a novel anti-epileptic drug (AED) which has recently been associated with reports of aplastic anaemia and liver failure."5.08Felbamate as add-on therapy. ( Duncan, JS; Li, LM; Moriarty, J; Nashef, L; Sander, JW, 1996)
"The objective of this study was to assess the psychiatric effects of the antiepileptic drug (AED) felbamate (FBM) in patients with epilepsy."5.08Felbamate monotherapy has stimulant-like effects in patients with epilepsy. ( Flamini, R; Ketter, TA; Ko, D; Malow, BA; Post, RM; Theodore, WH; White, SR, 1996)
"Subjects with epilepsy (three men and seven women; age range, 20 to 39 years; weight range, 53 to 88 kg) who were previously stabilized with valproic acid, 9."5.07The effect of felbamate on valproic acid disposition. ( Graves, NM; Leppik, IE; Perhach, JL; Remmel, RP; Shumaker, RC; Wagner, ML; Ward, DL, 1994)
"Felbamate (FBM, Felbatol/Taloxa), a new antiepileptic drug (AED), was tested in a placebo-controlled add-on design in 73 patients with therapy refractory Lennox-Gastaut syndrome."5.07Felbamate in the treatment of Lennox-Gastaut syndrome. ( Jensen, PK, 1994)
" The USA guideline for epilepsy treatment recommends that patients with newly diagnosed epilepsy can be treated with gabapentin, lamotrigine, topiramate, and oxcarbazepine."4.84[Newer antiepileptic drugs]. ( Matsuura, M, 2007)
"Since 1993, eight new antiepileptic drugs (AEDs) have become available in the United States for the treatment of epilepsy: felbamate, gabapentin, lamotrigine, topiramate, tiagabine, levetiracetam, oxcarbazepine, and zonisamide."4.81Some common issues in the use of antiepileptic drugs. ( Asconapé, JJ, 2002)
"The introduction of these new antiepileptic drugs, from felbamate to levetiracetam, raised hope of control of epilepsy with fewer adverse effects and improved quality of life."4.81New antiepileptic drug therapies. ( Bergin, AM; Connolly, M, 2002)
" More specifically, vigabatrin, which is a very useful and well tolerated new antiepileptic drug for refractory partial epilepsy, should be started at a low dosage of 0."4.79The new anticonvulsant drugs. Implications for avoidance of adverse effects. ( Krämer, G; Schmidt, D, 1994)
"After the first year of clinical experience, felbamate (FBM) appears to be a valuable antiepileptic drug (AED) for the treatment of intractable epilepsy."4.79Felbamate. ( Leppik, IE, 1995)
"Since 1994, three new antiepileptic drugs, felbamate, lamotrigene, and gabapentin, have been released for the treatment of epilepsy."4.79A review of the newer antiepileptic drugs and the ketogenic diet. ( Barron, TF; Hunt, SL, 1997)
"This article provides an analysis of the degree of agreement between in vivo interaction studies performed in patients with epilepsy and healthy individuals, and in vitro studies which identified the cytochromes P450 (CYP) inhibited by felbamate and those involved in its metabolism."4.79Pharmacokinetic interactions with felbamate. In vitro-in vivo correlation. ( Banfield, CR; Glue, P; Levy, RH; Mather, GG; Perhach, JL; Racha, JK, 1997)
" Felbamate (FBM) is effective in the treatment of partial seizures and Lennox-Gastaut epilepsy."4.78Advances in the pharmacotherapy of epilepsy. ( Ramsay, RE, 1993)
"This single center analysis retrospectively evaluated the safety and efficacy of felbamate in a cohort of children, adolescents, and adults with epilepsy."3.83Evaluating the safety and efficacy of felbamate in the context of a black box warning: A single center experience. ( Devinsky, O; Friedman, D; Kothare, SV; Shah, YD; Singh, K, 2016)
"Our patient's electrographic status epilepticus of sleep resolved after treatment with felbamate."3.81Successful Treatment of Electrographic Status Epilepticus of Sleep With Felbamate in a Patient With SLC9A6 Mutation. ( Coorg, R; Weisenberg, JL, 2015)
"To present our experience with felbamate therapy in children with drug-resistant epilepsy."3.80Efficacy and safety of felbamate in children with refractory epilepsy. ( Epstein, O; Gandelman-Marton, R; Heyman, E; Lahat, E; Levin, N, 2014)
"We present an implementation of a method we previously reported allowing the newer antiepileptic drugs (AEDs) rufinamide (RFN) and zonisamide (ZNS) to be simultaneously determined with lamotrigine (LTG), oxcarbazepine's (OXC) main active metabolite monohydroxycarbamazepine (MHD) and felbamate (FBM) in plasma of patients with epilepsy using high performance liquid chromatography (HPLC) with UV detection."3.76Simultaneous HPLC-UV analysis of rufinamide, zonisamide, lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in deproteinized plasma of patients with epilepsy. ( Albani, F; Baruzzi, A; Candela, C; Contin, M; Mohamed, S; Riva, R, 2010)
"The antiepileptic drug felbamate has demonstrated efficacy against a variety of seizure types in the pediatric population, particularly seizures associated with Lennox-Gastaut syndrome."3.76Efficacy of felbamate in the treatment of intractable pediatric epilepsy. ( Chico, MS; Eggener, KA; Hecox, KE; Marcuccilli, CJ; O'Connor, SE; Roell Werner, R; Schwabe, MS; Zupanc, ML, 2010)
"This article describes a simple isocratic high-performance liquid chromatographic (HPLC) method with UV detection for the determination of felbamate in the serum of patients with epilepsy."3.74Drug monitoring and toxicology: a simple procedure for the monitoring of felbamate by HPLC-UV detection. ( Tang, PH, 2008)
" By univariate analysis, those achieving seizure remission were probably much older, to have a shorter history of epilepsy and a lower frequency of seizures before felbamate therapy."3.74Efficacy and safety of felbamate in children under 4 years of age: a retrospective chart review. ( Balestri, P; Berardi, R; Coppola, G; Cordelli, DM; Franzoni, E; Grosso, S; Verrotti, A, 2008)
"A very simple and fast method has been developed and validated for simultaneous determination of the new generation antiepileptic drugs (AEDs) lamotrigine (LTG), oxcarbazepine's (OXC) main active metabolite monohydroxycarbamazepine and felbamate in plasma of patients with epilepsy using high-performance liquid chromatography (HPLC) with spectrophotometric detection."3.73Simultaneous liquid chromatographic determination of lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in plasma of patients with epilepsy. ( Albani, F; Balboni, M; Baruzzi, A; Callegati, E; Candela, C; Contin, M; Riva, R, 2005)
"The aim of the study was to assess the efficacy and safety of felbamate (FBM) as add-on therapy in pediatric patients with severe uncontrolled seizures during a 3-year follow-up."3.71The long-term use of felbamate in children with severe refractory epilepsy. ( Cilio, MR; Kartashov, AI; Vigevano, F, 2001)
"Influence Felbamate on the cerebral bioelectric activity (EEG) in the group of 31 children (18 with syndrome Lennox-Gastaut, 13 with partial epilepsy) with refractory epilepsy was investigated."3.70[Preliminary assessment of felbamate effect on the cerebral bioelectrical activity in children with refractory epilepsy]. ( Kuszczak, B; Mazur, J; Pakszys, M; Rusek, G; Szamotulska, K, 2000)
"The usefulness of felbamate (FBM) levels in managing epilepsy patients has not been determined."3.69Felbamate levels in patients with epilepsy. ( Harden, CL; Kutt, H; Trifiletti, R, 1996)
"We prospectively investigated drug-induced headaches (HA) among 60 epileptic patients receiving felbamate (FBM)."3.69Felbamate-induced headache. ( Andriola, MR; Berdia, A; Ettinger, AB; Jandorf, L; Krupp, LB; Weisbrot, DM, 1996)
"The behavioral effects of felbamate were assessed in 20 persons, (ages 2 to 19 years) who were participating in a compassionate plea protocol for children with Lennox-Gastaut syndrome."3.69Behavioral effects of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). ( Coskey, JS; Gay, PE; Mecham, GF; Sadler, T; Thompson, JA, 1995)
"Felbamate was compared with several antiepileptic drugs for protective effects in two rat models of status epilepticus."3.68Effects of felbamate and other anticonvulsant drugs in two models of status epilepticus in the rat. ( Diamantis, W; Gels, M; Gordon, R; Sofia, RD, 1993)
"The phenytoin treatment causes cerebellar defect and anemia."2.82The interplay of epilepsy with impaired mitophagy and autophagy linked dementia (MAD): A review of therapeutic approaches. ( Agrawal, M; Dhurandhar, Y; Panda, SP, 2022)
"This open-label study investigated the pharmacokinetic interaction of phenytoin (PHT) and felbamate (FBM)."2.69Coadministration of phenytoin and felbamate: evidence of additional phenytoin dose-reduction requirements based on pharmacokinetics and tolerability with increasing doses of felbamate. ( Lyness, WH; Perhach, JL; Rosenberg, A; Sachdeo, R; Sachdeo, S; Shumaker, RC; Wagner, ML; Ward, D, 1999)
"Felbamate (FBM) pharmacokinetic parameters, safety and tolerability in the dose range of 1,200-6,000 mg/day were assessed in two open-label studies with similar designs."2.68Tolerability and pharmacokinetics of monotherapy felbamate doses of 1,200-6,000 mg/day in subjects with epilepsy. ( Lyness, WH; Narang-Sachdeo, SK; Perhach, JL; Rosenberg, A; Sachdeo, R; Shumaker, RC, 1997)
"felbamate appears to be an effective new AED: the most adverse effects occurring during administration of FBM are mild to moderate gastrointestinal (nausea, vomiting and anorexia) and central nervous system (headache, sonnolence, diplopia, dizziness and insomnia) disturbances."2.68[Felbamate: a long-term study in subjects with refractory epilepsy]. ( De Romanis, F; Sopranzi, N, 1997)
"Felbamate is a novel antiepileptic drug that is now available in the United States."2.67Effect of felbamate on carbamazepine and its major metabolites. ( Graves, NM; Leppik, IE; Remmel, RP; Wagner, ML, 1993)
"Felbamate (FBM) is a new antiepileptic drug (AED) that has been evaluated in partial seizures and in the Lennox-Gastaut syndrome (LGS)."2.67Felbamate in the treatment of Lennox-Gastaut syndrome: results of a 12-month open-label study following a randomized clinical trial. ( Dodson, WE, 1993)
" Consequently, the controlled trial was designed to account for this interaction by reducing the phenytoin dosage by approximately 20% during the felbamate treatment period and using matching placebo capsules to maintain the blind."2.67Dosage adjustments in response to monitored plasma concentrations: can unblinded staff adhere to objective criteria? ( Pledger, GW; Sahlroot, JT, 1994)
"Safety and efficacy studies of new antiepileptic drugs require strict adherence to prescribed dosage regimens."2.66Compliant populations: variability in serum concentrations. ( Graves, NM; Holmes, GB; Leppik, IE, 1988)
" For drugs that are eliminated renally completely unchanged (gabapentin, pregabalin and vigabatrin) or mainly unchanged (levetiracetam and topiramate), the pharmacokinetic variability is less pronounced and more predictable."2.43Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? ( Johannessen, SI; Tomson, T, 2006)
"Felbamate has demonstrated efficacy against a variety of refractory seizures types, including seizures associated with Lennox-Gastaut syndrome, but postmarketing experience revealed serious idiosyncratic adverse effects that were not observed during clinical trials."2.43Felbamate: consensus of current clinical experience. ( Faught, E; Leppik, IE; Pellock, JM; Shinnar, S; Zupanc, ML, 2006)
"The pharmacokinetic properties of a drug are the primary deter-minant of the extent and duration of drug action, and influence susceptibility to clinically important drug interactions."2.42The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come? ( Johannessen, SI; Perucca, E, 2003)
" So the search for more effective drugs with minimal adverse effect profiles will continue."2.42Adverse effects of new antiepileptic drugs. ( Onat, F; Ozkara, C, 2004)
"Although antiepileptic drugs (AEDs) are commonly used to control and prevent seizures, their long-term use carries a considerable risk of morbidity."2.41Antiepileptic drug therapy for adults: when to initiate and how to choose. ( Sirven, JI, 2002)
"Epilepsy affects 1."2.41New antiepileptic drugs and preparations. ( Jagoda, A; Yoon, Y, 2000)
"Felbamate, however, has been linked with substantially increased incidence of aplastic anemia, and the other new AEDs have been studied for relatively short periods of time."2.40Pharmacologic and dietary therapies in epilepsy: conventional treatments and recent advances. ( Chapman, DP; Giles, WH, 1997)
"Felbamate (FBM) is a new antiepileptic drug (AED) that is often effective in seizure disorders refractory to other treatments; its use has been greatly restricted after cases of aplastic anemia were reported."2.40Evaluation of case reports of aplastic anemia among patients treated with felbamate. ( Anderson, T; Harmon, DC; Kaufman, DW; Kelly, JP; Shapiro, S, 1997)
"To most effectively treat children with epilepsy syndromes, further research must be completed to validate the positive effects described in case reports, open-label clinical trials, and early controlled clinical trials."2.40Managing pediatric epilepsy syndromes with new antiepileptic drugs. ( Pellock, JM, 1999)
"Successful treatment of seizure disorders in small animals requires proper patient assessment, understanding the principles of antiepileptic drug (AED) therapy, designing a strategy for pharmacotherapy, and plans for emergency treatment."2.40Antiepileptic drug therapy. ( Podell, M, 1998)
"Felbamate was launched in 1993 in the U."2.40Felbamate: clinical and molecular aspects of a unique antiepileptic drug. ( Aiken, SP; Brown, WM, 1998)
"Felbamate (FBM) was the first of the new antiepileptic drugs (AEDs) approved in the United States in 1993 with broad-spectrum efficacy against partial and generalized seizures of various types, and indicated for use as adjunctive and monotherapy."2.40Felbamate. ( Pellock, JM, 1999)
" For all drugs that are metabolized, half-life is shortened and clearance is increased when patients receive concomitant enzyme-inducing agents such as barbiturates, phenytoin, and carbamazepine."2.40The clinical pharmacokinetics of the new antiepileptic drugs. ( Perucca, E, 1999)
"Felbamate was submitted to innovative and unconventional clinical trials."2.40Felbamate. ( Bourgeois, BF, 1997)
"Standard antiepileptic drugs (AEDs) are associated with a wide variety of acute and chronic adverse events and with many interactions with each other and with non-AEDs that complicate patient management."2.40Overview of the safety of newer antiepileptic drugs. ( Shorvon, S; Stefan, H, 1997)
"Antiepileptic drugs (AEDs) in broad use today have a number of pharmacokinetic liabilities, including a propensity for clinically meaningful drug interactions."2.39Pharmacokinetic profile of topiramate in comparison with other new antiepileptic drugs. ( Perucca, E, 1996)
"Felbamate was licensed in 1993 for use as adjunctive therapy or monotherapy in adults with partial or tonic-clonic seizures and as adjunctive therapy for children with the Lennox-Gastaut syndrome."2.39Guidelines for treating epilepsy in the age of felbamate, vigabatrin, lamotrigine, and gabapentin. ( Laxer, KD, 1994)
"Felbamate is a new anticonvulsant which has already been marketed in some countries outside Germany, i."2.39[The pharmacologic and clinical profile of the new anticonvulsant felbamate--an overview]. ( Steinhoff, BJ, 1994)
"For many years, the medical treatment of epilepsy was based on the use of the same few drugs, which were chosen according to the seizure type in a fairly standardized manner."2.39New antiepileptic drugs. ( Bourgeois, BF, 1996)
" Specific indications and dosage schedules have been provided."2.39New antiepileptic drugs. ( Brodie, MJ; Wilson, EA, 1996)
"Epilepsy is one of the most common neurological disorders."2.39Newer antiepileptic drugs. Towards an improved risk-benefit ratio. ( Patsalos, PN; Sander, JW, 1994)
"This article surveys the pharmacokinetic parameters for the new antiepileptic drugs (AEDs): felbamate, gabapentin, lamotrigine, oxcarbazepine, tiagabine, topiramate, and vigabatrin."2.39Pharmacokinetics of new antiepileptic drugs. ( Gram, L, 1996)
"Felbamate has been used effectively as monotherapy and adjunctive therapy in patients with partial seizures with or without secondary generalization and as adjunctive therapy in children with partial or generalized seizures associated with Lennox-Gastaut syndrome."2.39Felbamate: a new antiepileptic drug. ( Wagner, ML, 1994)
" ZNS daily dosage is 400-600 mg."2.39Antiepileptic drugs in development: prospects for the near future. ( Leppik, IE, 1994)
"Epilepsy is common in individuals who are mentally retarded and/or otherwise multiply handicapped."2.39The role of the old and the new antiepileptic drugs in special populations: mental and multiple handicaps. ( Mattson, RH, 1996)
" Clinical evaluation of AEDs is both difficult and complex, due mainly to two factors: (1) intermittence of clinical events, which means that dosing for periods of several weeks is generally necessary, leading to problems of poor compliance and inaccurate reporting of events by carers and patients; and (2) therapeutic necessity, which means that it is, in general, unacceptable to withhold effective treatment from a person with epilepsy."2.39Design of clinical antiepileptic drug trials. ( Binnie, CD, 1995)
"Epilepsy is a disorder of the central nervous system in which the clinical symptoms are recurrent seizures."2.38Advances in pharmacotherapy: recent developments in the treatment of epilepsy. ( Graves, NM; Leppik, IE, 1993)
"Felbamate (FBM) is an effective and safe novel antiepileptic drug (AED) for add-on treatment in adults with refractory partial seizures as shown in three pivotal controlled trials."2.38Felbamate: successful development of a new compound for the treatment of epilepsy. ( Schmidt, D, 1993)
"9%) seizure frequency was reduced by more than 50% (mean FBM dosage 3211 mg), and 13 patients (31."1.34[Treatment of epilepsy with third-line antiepileptic drugs: felbamate, tiagabine, and sulthiame]. ( Bauer, J; Chahem, J, 2007)
"Felbamate is an antiepileptic drug that is associated with minimal toxicity in preclinical species such as rat and dog but has an unacceptable incidence of serious idiosyncratic reactions in man."1.34Evaluation of felbamate and other antiepileptic drug toxicity potential based on hepatic protein covalent binding and gene expression. ( Johnson, MD; Kao, LM; Kelley, MF; Leone, AM; Lord, PG; McMillian, MK; Nie, AY; Parker, JB; Parkinson, A; Usuki, E, 2007)
" LEV and FBM brain concentrations were measured by HPLC in order to determine any pharmacokinetic contribution to the observed antiseizure effect."1.34Levetiracetam and felbamate interact both pharmacodynamically and pharmacokinetically: an isobolographic analysis in the mouse maximal electroshock model. ( Andres-Mach, MM; Czuczwar, SJ; Luszczki, JJ; Patsalos, PN; Ratnaraj, N, 2007)
"The lamotrigine level was 14."1.33Lamotrigine as a possible cause of QRS prolongation in a patient with known seizure disorder. ( Herold, TJ, 2006)
"Felbamate therapy was consider to be the turning-point in both therapeutic and diagnostic meaning."1.31[Positive effect of falbamate therapy in a boy with refractory epilepsy]. ( Pakszys, M; Rusek, G; Szczepanik, E, 2000)
"Felbamate (FBM) was initiated and VPA discontinued for improved seizure control."1.30Male infertility: possible association with valproate exposure. ( McCoy, GB; Yerby, MS, 1999)
"Pretreatment with felbamate at either dose prevented the progression of rank of seizures during chronic treatment with PTZ."1.29Anticonvulsant effect of felbamate in the pentylenetetrazole kindling model of epilepsy in the rat. ( Carboni, G; Corda, MG; Feldman, A; Frau, V; Giorgi, O; Orlandi, M; Valentini, V, 1996)
"The patient experienced complete seizure control and almost complete return of language skills following the addition of felbamate."1.29Felbamate in the treatment of acquired epileptic aphasia. ( Glauser, TA; Olberding, LS; Piccirillo, DM; Titanic, MK, 1995)
"Felbamate is a new antiepileptic drug (AED) with a good safety profile."1.29Weight loss in patients taking felbamate. ( Bergen, DC; Hoeppner, TJ; Kanner, A; Ristanovic, RK; Waicosky, K, 1995)

Research

Studies (142)

TimeframeStudies, this research(%)All Research%
pre-19902 (1.41)18.7374
1990's95 (66.90)18.2507
2000's35 (24.65)29.6817
2010's7 (4.93)24.3611
2020's3 (2.11)2.80

Authors

AuthorsStudies
Panda, SP1
Dhurandhar, Y1
Agrawal, M1
Tomson, T2
Battino, D1
Bromley, R1
Kochen, S1
Meador, KJ1
Pennell, PB1
Thomas, SV1
Hussain, SA1
Asilnejad, B1
Heesch, J1
Navarro, M1
Ji, M1
Shrey, DW1
Rajaraman, RR1
Sankar, R1
Heyman, E1
Levin, N1
Lahat, E1
Epstein, O1
Gandelman-Marton, R1
Coorg, R1
Weisenberg, JL1
Shah, YD1
Singh, K1
Friedman, D1
Devinsky, O2
Kothare, SV1
Tang, PH1
Grosso, S1
Cordelli, DM1
Coppola, G1
Franzoni, E1
Verrotti, A1
Berardi, R1
Balestri, P1
Hill, AJ1
Jones, NA1
Williams, CM1
Stephens, GJ1
Whalley, BJ1
Contin, M2
Mohamed, S1
Candela, C2
Albani, F2
Riva, R2
Baruzzi, A2
Cavanna, AE1
Ali, F1
Rickards, HE1
McCorry, D1
Zupanc, ML2
Roell Werner, R1
Schwabe, MS1
O'Connor, SE1
Marcuccilli, CJ1
Hecox, KE1
Chico, MS1
Eggener, KA1
Potschka, H2
Fedrowitz, M2
Löscher, W2
Asconapé, JJ1
Héberlé, C1
Berquin, P1
Larnicol, N1
Wallois, F1
Sirven, JI1
Bergin, AM1
Connolly, M1
Perucca, E3
Johannessen, SI2
Onat, F1
Ozkara, C1
Luszczki, JJ2
Czuczwar, SJ2
Harrison, PK1
Sheridan, RD1
Green, AC1
Tattersall, JE1
Balboni, M1
Callegati, E1
Pellock, JM8
Faught, E2
Leppik, IE8
Shinnar, S1
Roecklein, BA1
Sacks, HJ1
Mortko, H1
Stables, J1
Andres-Mach, MM1
Ratnaraj, N1
Patsalos, PN2
Matsuura, M1
Herold, TJ1
Leone, AM1
Kao, LM1
McMillian, MK1
Nie, AY1
Parker, JB1
Kelley, MF1
Usuki, E1
Parkinson, A1
Lord, PG1
Johnson, MD1
Chahem, J1
Bauer, J1
Dannhardt, G1
Kiefer, W1
Hwang, H1
Kim, KJ1
Macdonald, RL1
Kelly, KM1
Binnie, CD1
Theodore, WH4
Albert, P1
Stertz, B2
Malow, B2
Ko, D3
White, S1
Flamini, R3
Ketter, T1
Kupecz, D1
Palmer, KJ1
McTavish, D1
Glauser, TA2
Olberding, LS1
Titanic, MK1
Piccirillo, DM1
Schmidt, D2
Krämer, G1
Herranz, JL2
Arteaga, R1
Armijo, JA1
Vazquez, B1
Luciano, D1
Sander, JW2
Grossmann, R1
Maytal, J1
Fernando, J1
Wagner, ML4
Luer, MS1
Buchanan, N1
Graves, NM4
Remmel, RP2
Shumaker, RC4
Ward, DL1
Perhach, JL7
Laxer, KD1
Steinhoff, BJ1
Sahlroot, JT2
Pledger, GW2
Jensen, PK1
Parks, BR1
Dostrow, VG1
Noble, SL1
Byers, VL1
Skolnick, AA1
Manack, L1
Dodson, WE1
Ramsay, RE2
Slater, JD1
Shields, WD1
Herranz Fernández, JL1
Nightingale, SL1
Heinzl, S1
Sofia, RD4
Gordon, R1
Gels, M1
Diamantis, W1
Lee, EK1
Harden, CL1
Trifiletti, R1
Kutt, H1
Ettinger, AB1
Jandorf, L1
Berdia, A1
Andriola, MR1
Krupp, LB1
Weisbrot, DM1
Gay, PE1
Mecham, GF1
Coskey, JS1
Sadler, T1
Thompson, JA1
Legido, A1
Bergen, DC1
Ristanovic, RK1
Waicosky, K1
Kanner, A1
Hoeppner, TJ1
Iivanainen, M1
Gaily, E1
Li, LM1
Nashef, L1
Moriarty, J1
Duncan, JS1
Giorgi, O1
Carboni, G1
Frau, V1
Orlandi, M1
Valentini, V1
Feldman, A1
Corda, MG1
Hussein, G1
Troupin, AS1
Montouris, G2
Gram, L1
Meldrum, BS1
Mattson, RH1
Avanzini, G1
Canger, R1
Dalla Bernardina, B1
Vigevano, F2
Ketter, TA2
Malow, BA2
White, SR1
Post, RM2
Grippo, J1
Appleton, RE1
Bourgeois, BF3
Morris, HH1
Wilson, EA1
Brodie, MJ2
Shorvon, S1
Stefan, H1
Padró, L1
Arbizu, T1
Rovira, R1
Chapman, DP1
Giles, WH1
Wyler, AR1
Vossler, DG1
Barron, TF1
Hunt, SL1
Glue, P1
Banfield, CR1
Mather, GG1
Racha, JK1
Levy, RH1
Burdette, DE1
Sackellares, JC1
De Romanis, F1
Sopranzi, N1
Sunder, TR1
Bazil, CW1
Pedley, TA1
Sachdeo, RC1
Narang-Sachdeo, S1
Montgomery, PA1
Lyness, WH3
Rosenberg, A4
Kaufman, DW1
Kelly, JP1
Anderson, T1
Harmon, DC1
Shapiro, S1
Sachdeo, R2
Narang-Sachdeo, SK1
Stefani, A1
Spadoni, F1
Bernardi, G1
De Sarro, GB1
Berlinghieri, MC1
Elia, M1
Musumeci, SA1
David, E1
Dominijanni, A1
Gulletta, E1
Podell, M1
Marciani, MG1
Spanedda, F1
Placidi, F1
Bassetti, MA1
Romigi, A1
Mattia, D1
Brown, WM1
Aiken, SP1
Wilner, AN1
Siegel, H1
Kelley, K1
Reeves-Tyer, P1
Gaillard, WD1
Yerby, MS1
McCoy, GB1
French, J1
Smith, M1
Brown, L1
Thompson, CD2
Barthen, MT2
Hopper, DW1
Miller, TA2
Quigg, M1
Hudspeth, C1
Marsh, L1
Macdonald, TL2
Sachdeo, S1
Ward, D1
Appleton, R1
Benbadis, S1
Dieckhaus, CM1
Szczepanik, E1
Pakszys, M2
Rusek, G2
Kuszczak, B1
Szamotulska, K1
Mazur, J1
Vajda, FJ1
Rogawski, MA1
Wasterlain, CG1
Mazarati, AM1
Foletti, GB1
Yoon, Y1
Jagoda, A1
Sparagana, SP1
Strand, WR1
Adams, RC1
French, JA1
Cilio, MR1
Kartashov, AI1
Kramer, L1
Porter, RJ1
Holmes, GB1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Effect of Normalization of Sodium on Bone Markers in Patients With Epilepsy. A Randomized Single-blinded Placebo-controlled Trial.[NCT03371199]21 participants (Actual)Interventional2017-12-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

73 reviews available for felbamate and Aura

ArticleYear
The interplay of epilepsy with impaired mitophagy and autophagy linked dementia (MAD): A review of therapeutic approaches.
    Mitochondrion, 2022, Volume: 66

    Topics: Anticonvulsants; Carbamazepine; Dementia; Epilepsy; Felbamate; Gabapentin; Humans; Inflammasomes; La

2022
Breastfeeding while on treatment with antiseizure medications: a systematic review from the ILAE Women Task Force
    Epileptic disorders : international epilepsy journal with videotape, 2022, 12-01, Volume: 24, Issue:6

    Topics: Breast Feeding; Cannabidiol; Carbamazepine; Child; Clobazam; Clonazepam; Epilepsy; Ethosuximide; Eve

2022
Behavioral and cognitive effects of anti-epileptic drugs.
    Discovery medicine, 2010, Volume: 9, Issue:45

    Topics: Amines; Anticonvulsants; Antidepressive Agents; Behavior; Cognition; Cognition Disorders; Cyclohexan

2010
Some common issues in the use of antiepileptic drugs.
    Seminars in neurology, 2002, Volume: 22, Issue:1

    Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Anticonvulsants; Body Weight; Cognition Disorders; Drug E

2002
Antiepileptic drug therapy for adults: when to initiate and how to choose.
    Mayo Clinic proceedings, 2002, Volume: 77, Issue:12

    Topics: Acetates; Adult; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Epilepsy; Felb

2002
New antiepileptic drug therapies.
    Neurologic clinics, 2002, Volume: 20, Issue:4

    Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Child; Cyclohexanecarboxylic Acids; Dioxolanes; Ep

2002
The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come?
    Epileptic disorders : international epilepsy journal with videotape, 2003, Volume: 5 Suppl 1

    Topics: Acetates; Amines; Animals; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Interac

2003
Adverse effects of new antiepileptic drugs.
    Drugs of today (Barcelona, Spain : 1998), 2004, Volume: 40, Issue:4

    Topics: Adult; Anticonvulsants; Child; Clinical Trials as Topic; Epilepsy; Felbamate; Humans; Phenylcarbamat

2004
Felbamate: consensus of current clinical experience.
    Epilepsy research, 2006, Volume: 71, Issue:2-3

    Topics: Anticonvulsants; Drug Interactions; Drug Therapy, Combination; Epilepsy; Felbamate; Humans; Language

2006
Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?
    Clinical pharmacokinetics, 2006, Volume: 45, Issue:11

    Topics: Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Interactions; Drug Monitor

2006
Fluorofelbamate.
    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2007, Volume: 4, Issue:1

    Topics: Animals; Anticonvulsants; Brain; Clinical Trials as Topic; Epilepsy; Felbamate; Humans; Phenylcarbam

2007
[Newer antiepileptic drugs].
    No to shinkei = Brain and nerve, 2007, Volume: 59, Issue:2

    Topics: Amines; Animals; Anti-Anxiety Agents; Anticonvulsants; Calcium Channel Blockers; Carbamazepine; Cycl

2007
[New antiepileptics in development].
    Pharmazie in unserer Zeit, 2007, Volume: 36, Issue:4

    Topics: Animals; Anticonvulsants; Benzodiazepines; Carbamazepine; Epilepsy; Felbamate; Humans; Levetiracetam

2007
Mechanisms of action of currently prescribed and newly developed antiepileptic drugs.
    Epilepsia, 1994, Volume: 35 Suppl 4

    Topics: Acetates; Amines; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Drugs, Investigational; Epi

1994
Design of clinical antiepileptic drug trials.
    Seizure, 1995, Volume: 4, Issue:3

    Topics: Anticonvulsants; Bias; Clinical Trials, Phase II as Topic; Controlled Clinical Trials as Topic; Drug

1995
Felbamate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in epilepsy.
    Drugs, 1993, Volume: 45, Issue:6

    Topics: Adolescent; Adult; Animals; Anticonvulsants; Child; Child, Preschool; Drug Interactions; Epilepsy; F

1993
The new anticonvulsant drugs. Implications for avoidance of adverse effects.
    Drug safety, 1994, Volume: 11, Issue:6

    Topics: Abnormalities, Drug-Induced; Anemia, Aplastic; Anticonvulsants; Chemical and Drug Induced Liver Inju

1994
[New antiepileptic drugs: vagabatrin, lamotrigine and felbamate].
    Neurologia (Barcelona, Spain), 1994, Volume: 9, Issue:9

    Topics: Anticonvulsants; Epilepsy; Felbamate; gamma-Aminobutyric Acid; Humans; Lamotrigine; Phenylcarbamates

1994
New antiepileptic drugs for children: felbamate, gabapentin, lamotrigine, and vigabatrin.
    Journal of child neurology, 1994, Volume: 9 Suppl 1

    Topics: Acetates; Adult; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Drug Approval; Epileps

1994
Newer antiepileptic drugs. Towards an improved risk-benefit ratio.
    Drug safety, 1994, Volume: 11, Issue:1

    Topics: Acetamides; Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Dioxolane

1994
Felbamate: a new antiepileptic drug.
    American journal of hospital pharmacy, 1994, Jul-01, Volume: 51, Issue:13

    Topics: Anticonvulsants; Chromatography, High Pressure Liquid; Clinical Trials as Topic; Drug Interactions;

1994
New anti-epileptic drugs in the 1990s.
    Journal of paediatrics and child health, 1994, Volume: 30, Issue:4

    Topics: Acetates; Amines; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clobazam

1994
Guidelines for treating epilepsy in the age of felbamate, vigabatrin, lamotrigine, and gabapentin.
    The Western journal of medicine, 1994, Volume: 161, Issue:3

    Topics: Acetates; Adult; Amines; Animals; Anticonvulsants; Child; Clinical Protocols; Controlled Clinical Tr

1994
[The pharmacologic and clinical profile of the new anticonvulsant felbamate--an overview].
    Fortschritte der Neurologie-Psychiatrie, 1994, Volume: 62, Issue:10

    Topics: Adult; Anticonvulsants; Child; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epilepsy

1994
Drug therapy for epilepsy.
    American family physician, 1994, Sep-01, Volume: 50, Issue:3

    Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Decision Trees; Epilepsy; Felbamate;

1994
Antiepileptic drugs in development: prospects for the near future.
    Epilepsia, 1994, Volume: 35 Suppl 4

    Topics: Acetates; Adult; Amines; Aminocaproates; Animals; Anticonvulsants; Clinical Trials as Topic; Cyclohe

1994
Advances in pharmacotherapy: recent developments in the treatment of epilepsy.
    Journal of clinical pharmacy and therapeutics, 1993, Volume: 18, Issue:4

    Topics: Acetates; Amines; Aminocaproates; Animals; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Aci

1993
Felbamate: successful development of a new compound for the treatment of epilepsy.
    Epilepsia, 1993, Volume: 34 Suppl 7

    Topics: Adult; Anticonvulsants; Child; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy,

1993
Antiepileptic drugs in clinical development.
    Epilepsy research. Supplement, 1993, Volume: 10

    Topics: Acetates; Amines; Aminocaproates; Anticonvulsants; Brain; Clinical Trials as Topic; Cyclohexanecarbo

1993
Investigational antiepileptic drugs for the treatment of childhood seizure disorders: a review of efficacy and safety.
    Epilepsia, 1994, Volume: 35 Suppl 2

    Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Child; Clinical Trials as

1994
[Contribution of new drugs to the better control of epilepsy].
    Anales espanoles de pediatria, 1993, Volume: 39 Suppl 55

    Topics: Aminocaproates; Anticonvulsants; Child; Delayed-Action Preparations; Epilepsy; Felbamate; Humans; Ph

1993
Advances in the pharmacotherapy of epilepsy.
    Epilepsia, 1993, Volume: 34 Suppl 5

    Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Felbamate; Gabapentin; gam

1993
Pharmacokinetic profile of topiramate in comparison with other new antiepileptic drugs.
    Epilepsia, 1996, Volume: 37 Suppl 2

    Topics: Acetates; Amines; Anticonvulsants; Biological Availability; Carbamazepine; Clinical Trials as Topic;

1996
Utilization of new antiepileptic drugs in children.
    Epilepsia, 1996, Volume: 37 Suppl 1

    Topics: Acetates; Adolescent; Adult; Age Factors; Amines; Anticonvulsants; Carbamazepine; Child; Child, Pres

1996
[Advances in the diagnostic and treatment of infantile epilepsy].
    Revista de neurologia, 1996, Volume: 24, Issue:130

    Topics: Acetates; Amines; Anticonvulsants; Brain; Child; Child, Preschool; Cyclohexanecarboxylic Acids; Elec

1996
[Current anti-epilepsy drugs].
    Duodecim; laaketieteellinen aikakauskirja, 1995, Volume: 111, Issue:8

    Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Therapy, Combina

1995
Felbamate.
    Epilepsia, 1995, Volume: 36 Suppl 2

    Topics: Adult; Anticonvulsants; Child; Clinical Trials as Topic; Drug Administration Schedule; Drug Interact

1995
Pharmacokinetics of new antiepileptic drugs.
    Epilepsia, 1996, Volume: 37 Suppl 6

    Topics: Acetates; Amines; Anticonvulsants; Biological Availability; Carbamazepine; Cyclohexanecarboxylic Aci

1996
Update on the mechanism of action of antiepileptic drugs.
    Epilepsia, 1996, Volume: 37 Suppl 6

    Topics: 4-Aminobutyrate Transaminase; Acetamides; Acetates; Amines; Animals; Anticonvulsants; Cyclohexanecar

1996
The role of the old and the new antiepileptic drugs in special populations: mental and multiple handicaps.
    Epilepsia, 1996, Volume: 37 Suppl 6

    Topics: Acetates; Amines; Anticonvulsants; Cerebral Palsy; Cyclohexanecarboxylic Acids; Disabled Persons; Dr

1996
[Advantages and disadvantages of new antiepileptic drugs].
    Revista de neurologia, 1996, Volume: 24, Issue:135

    Topics: Acetates; Adrenocorticotropic Hormone; Amines; Anticonvulsants; Brain; Cyclohexanecarboxylic Acids;

1996
[Treatment of the epilepsy: new drugs].
    Revista de neurologia, 1996, Volume: 24, Issue:135

    Topics: Acetates; Amines; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Carbamaz

1996
The new antiepileptic drugs.
    Archives of disease in childhood, 1996, Volume: 75, Issue:3

    Topics: Abnormalities, Drug-Induced; Acetates; Adolescent; Adult; Amines; Anticonvulsants; Child; Child, Pre

1996
New antiepileptic drugs.
    Current opinion in pediatrics, 1996, Volume: 8, Issue:6

    Topics: Acetates; Adult; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Epilepsy; Felbamate; F

1996
New antiepileptic drugs.
    Bailliere's clinical neurology, 1996, Volume: 5, Issue:4

    Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Epilepsy; Felbamate;

1996
Overview of the safety of newer antiepileptic drugs.
    Epilepsia, 1997, Volume: 38 Suppl 1

    Topics: Acetates; Amines; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Drug Inter

1997
Felbamate.
    Seminars in pediatric neurology, 1997, Volume: 4, Issue:1

    Topics: Anticonvulsants; Child; Epilepsy; Felbamate; Humans; Phenylcarbamates; Propylene Glycols

1997
[New antiepileptic drugs].
    Revista de neurologia, 1997, Volume: 25, Issue:138

    Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Felbamate; Gabapentin; gam

1997
Pharmacologic and dietary therapies in epilepsy: conventional treatments and recent advances.
    Southern medical journal, 1997, Volume: 90, Issue:5

    Topics: Acetates; Amines; Anticonvulsants; Benzodiazepines; Carbamazepine; Cyclohexanecarboxylic Acids; Epil

1997
Recent advancements in epilepsy.
    Surgical neurology, 1997, Volume: 48, Issue:2

    Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Felbamate; Fructose; Gabap

1997
A review of the newer antiepileptic drugs and the ketogenic diet.
    Clinical pediatrics, 1997, Volume: 36, Issue:9

    Topics: Acetates; Age Factors; Amines; Anticonvulsants; Child; Child, Preschool; Cyclohexanecarboxylic Acids

1997
Pharmacokinetic interactions with felbamate. In vitro-in vivo correlation.
    Clinical pharmacokinetics, 1997, Volume: 33, Issue:3

    Topics: Anticonvulsants; Area Under Curve; Carbamazepine; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-4

1997
Felbamate pharmacology and use in epilepsy.
    Clinical neuropharmacology, 1994, Volume: 17, Issue:5

    Topics: Animals; Anticonvulsants; Epilepsy; Felbamate; Humans; Phenylcarbamates; Propylene Glycols

1994
Meeting the challenge of epilepsy in persons with multiple handicaps.
    Journal of child neurology, 1997, Volume: 12 Suppl 1

    Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Comorbidity; Developmental Disabilities

1997
Overview of lamotrigine and the new antiepileptic drugs: the challenge.
    Journal of child neurology, 1997, Volume: 12 Suppl 1

    Topics: Acetates; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Drug Interactions; Epilepsy;

1997
Advances in the medical treatment of epilepsy.
    Annual review of medicine, 1998, Volume: 49

    Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Diazepam; Drug Approv

1998
Evaluation of case reports of aplastic anemia among patients treated with felbamate.
    Epilepsia, 1997, Volume: 38, Issue:12

    Topics: Adult; Adverse Drug Reaction Reporting Systems; Anemia, Aplastic; Anticonvulsants; Causality; Confou

1997
Voltage-activated calcium channels: targets of antiepileptic drug therapy?
    Epilepsia, 1997, Volume: 38, Issue:9

    Topics: Animals; Anticonvulsants; Calcium Channels; Carbamazepine; Drug Design; Epilepsy; Felbamate; Humans;

1997
Role of new and established antiepileptic drugs.
    Epilepsia, 1998, Volume: 39 Suppl 5

    Topics: Animals; Anticonvulsants; Clinical Trials as Topic; Drug Interactions; Epilepsies, Partial; Epilepsy

1998
New antiepileptic drugs.
    Archives of neurology, 1998, Volume: 55, Issue:9

    Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Approval; Epilep

1998
Antiepileptic drug therapy.
    Clinical techniques in small animal practice, 1998, Volume: 13, Issue:3

    Topics: Acetates; Amines; Animals; Anticonvulsants; Bromides; Cat Diseases; Cats; Cyclohexanecarboxylic Acid

1998
Felbamate: clinical and molecular aspects of a unique antiepileptic drug.
    Critical reviews in neurobiology, 1998, Volume: 12, Issue:3

    Topics: Animals; Anticonvulsants; Clinical Trials as Topic; Drug Resistance; Epilepsy; Felbamate; Humans; In

1998
New medication options for patients with epilepsy.
    Medicine and health, Rhode Island, 1998, Volume: 81, Issue:12

    Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Felbamate; Fructose; Gabap

1998
Felbamate in epilepsy therapy: evaluating the risks.
    Drug safety, 1999, Volume: 21, Issue:3

    Topics: Animals; Anticonvulsants; Epilepsy; Felbamate; Female; Humans; Male; Phenylcarbamates; Propylene Gly

1999
Use of new antiepileptic drugs in the treatment of childhood epilepsy.
    Epilepsia, 1999, Volume: 40 Suppl 6

    Topics: Acetates; Adult; Age Factors; Amines; Anticonvulsants; Child; Clinical Trials as Topic; Cyclohexanec

1999
Felbamate.
    Epilepsia, 1999, Volume: 40 Suppl 5

    Topics: Adult; Age Factors; Anemia, Aplastic; Anorexia; Anticonvulsants; Child; Drug Administration Schedule

1999
Managing pediatric epilepsy syndromes with new antiepileptic drugs.
    Pediatrics, 1999, Volume: 104, Issue:5 Pt 1

    Topics: Acetates; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Epilepsy; Felbamate; Fructose

1999
The clinical pharmacokinetics of the new antiepileptic drugs.
    Epilepsia, 1999, Volume: 40 Suppl 9

    Topics: Acetates; Amines; Anticonvulsants; Biological Availability; Cyclohexanecarboxylic Acids; Dose-Respon

1999
New antiepileptic drugs.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2000, Volume: 7, Issue:2

    Topics: Acetates; Amines; Animals; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Interac

2000
Idiosyncratic reactions: new methods of identifying high-risk patients.
    Epilepsia, 2000, Volume: 41 Suppl 8

    Topics: Anticonvulsants; Biomarkers; Drug Monitoring; Epilepsy; Epoxide Hydrolases; Felbamate; Free Radical

2000
New antiepileptic drugs and preparations.
    Emergency medicine clinics of North America, 2000, Volume: 18, Issue:4

    Topics: Acetates; Administration, Rectal; Age Factors; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids;

2000
The role of new antiepileptic drugs.
    The American journal of managed care, 2001, Volume: 7, Issue:7 Suppl

    Topics: Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Epilepsies, Partial; Epilepsy; Epi

2001
Felbamate.
    Epilepsy research. Supplement, 1991, Volume: 3

    Topics: Administration, Oral; Animals; Anticonvulsants; Dose-Response Relationship, Drug; Drugs, Investigati

1991

Trials

16 trials available for felbamate and Aura

ArticleYear
Felbamate monotherapy: implications for antiepileptic drug development.
    Epilepsia, 1995, Volume: 36, Issue:11

    Topics: Adolescent; Adult; Anticonvulsants; Double-Blind Method; Drug Administration Schedule; Drugs, Invest

1995
The effect of felbamate on valproic acid disposition.
    Clinical pharmacology and therapeutics, 1994, Volume: 56, Issue:5

    Topics: Adult; Cross-Over Studies; Drug Therapy, Combination; Epilepsy; Felbamate; Female; Humans; Male; Phe

1994
Dosage adjustments in response to monitored plasma concentrations: can unblinded staff adhere to objective criteria?
    Journal of biopharmaceutical statistics, 1994, Volume: 4, Issue:1

    Topics: Attitude of Health Personnel; Carbamazepine; Dose-Response Relationship, Drug; Double-Blind Method;

1994
Felbamate in the treatment of Lennox-Gastaut syndrome.
    Epilepsia, 1994, Volume: 35 Suppl 5

    Topics: Adult; Anticonvulsants; Child; Drugs, Investigational; Epilepsies, Partial; Epilepsy; Felbamate; Fol

1994
Felbamate in the treatment of Lennox-Gastaut syndrome: results of a 12-month open-label study following a randomized clinical trial.
    Epilepsia, 1993, Volume: 34 Suppl 7

    Topics: Anticonvulsants; Child; Dose-Response Relationship, Drug; Double-Blind Method; Electroencephalograph

1993
Effect of felbamate on carbamazepine and its major metabolites.
    Clinical pharmacology and therapeutics, 1993, Volume: 53, Issue:5

    Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Double-Blind Method; Drug Interactions; Epilepsy;

1993
Felbamate as add-on therapy.
    European neurology, 1996, Volume: 36, Issue:3

    Topics: Adult; Anemia, Aplastic; Anticonvulsants; Epilepsy; Felbamate; Follow-Up Studies; Humans; Liver Fail

1996
Felbamate in therapy-resistant epilepsy: an Italian experience. Felbamate Italian Study Group.
    Epilepsy research, 1996, Volume: 25, Issue:3

    Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Anticonvulsants; Child; Child, Preschool; Drug Resistance

1996
Felbamate monotherapy has stimulant-like effects in patients with epilepsy.
    Epilepsy research, 1996, Volume: 23, Issue:2

    Topics: Adult; Anticonvulsants; Epilepsy; Felbamate; Female; Humans; Male; Phenylcarbamates; Propylene Glyco

1996
[Felbamate: a long-term study in subjects with refractory epilepsy].
    La Clinica terapeutica, 1997, Volume: 148, Issue:3

    Topics: Adolescent; Adult; Anticonvulsants; Dose-Response Relationship, Drug; Epilepsies, Partial; Epilepsy;

1997
Evaluation of the potential interaction between felbamate and erythromycin in patients with epilepsy.
    Journal of clinical pharmacology, 1998, Volume: 38, Issue:2

    Topics: Adult; Anti-Bacterial Agents; Anticonvulsants; Cross-Over Studies; Drug Interactions; Epilepsy; Eryt

1998
Tolerability and pharmacokinetics of monotherapy felbamate doses of 1,200-6,000 mg/day in subjects with epilepsy.
    Epilepsia, 1997, Volume: 38, Issue:8

    Topics: Adolescent; Adult; Anorexia; Anticonvulsants; Area Under Curve; Dose-Response Relationship, Drug; Dr

1997
The efficacy of felbamate as add-on therapy to valproic acid in the Lennox-Gastaut syndrome.
    Epilepsy research, 1999, Volume: 34, Issue:2-3

    Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Cross-Over Studies; Double-Blind Method; Drug

1999
Coadministration of phenytoin and felbamate: evidence of additional phenytoin dose-reduction requirements based on pharmacokinetics and tolerability with increasing doses of felbamate.
    Epilepsia, 1999, Volume: 40, Issue:8

    Topics: Adult; Anticonvulsants; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interac

1999
The synthesis, in vitro reactivity, and evidence for formation in humans of 5-phenyl-1,3-oxazinane-2,4-dione, a metabolite of felbamate.
    Drug metabolism and disposition: the biological fate of chemicals, 2000, Volume: 28, Issue:4

    Topics: Anticonvulsants; Biotransformation; Chromatography, High Pressure Liquid; Epilepsy; Felbamate; Human

2000
Compliant populations: variability in serum concentrations.
    Epilepsy research. Supplement, 1988, Volume: 1

    Topics: Anticonvulsants; Carbamazepine; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combina

1988

Other Studies

53 other studies available for felbamate and Aura

ArticleYear
Felbamate in the treatment of refractory epileptic spasms.
    Epilepsy research, 2020, Volume: 161

    Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Epilepsy; Felbamate; Female; Humans; Infant; M

2020
Efficacy and safety of felbamate in children with refractory epilepsy.
    European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, 2014, Volume: 18, Issue:6

    Topics: Anticonvulsants; Child; Child, Preschool; Electroencephalography; Epilepsy; Felbamate; Female; Human

2014
Successful Treatment of Electrographic Status Epilepticus of Sleep With Felbamate in a Patient With SLC9A6 Mutation.
    Pediatric neurology, 2015, Volume: 53, Issue:6

    Topics: Anticonvulsants; Ataxia; Child; Epilepsy; Felbamate; Genetic Diseases, X-Linked; Humans; Intellectua

2015
Evaluating the safety and efficacy of felbamate in the context of a black box warning: A single center experience.
    Epilepsy & behavior : E&B, 2016, Volume: 56

    Topics: Adolescent; Adult; Age of Onset; Anemia, Aplastic; Anticonvulsants; Child; Cohort Studies; Drug Labe

2016
Drug monitoring and toxicology: a simple procedure for the monitoring of felbamate by HPLC-UV detection.
    Journal of analytical toxicology, 2008, Volume: 32, Issue:5

    Topics: Anticonvulsants; Chromatography, High Pressure Liquid; Drug Monitoring; Epilepsy; Felbamate; Humans;

2008
Efficacy and safety of felbamate in children under 4 years of age: a retrospective chart review.
    European journal of neurology, 2008, Volume: 15, Issue:9

    Topics: Anorexia; Anticonvulsants; Child, Preschool; Drug Evaluation; Drug Resistance; Epilepsy; Felbamate;

2008
Development of multi-electrode array screening for anticonvulsants in acute rat brain slices.
    Journal of neuroscience methods, 2010, Jan-15, Volume: 185, Issue:2

    Topics: 4-Aminopyridine; Animals; Animals, Newborn; Anticonvulsants; Disease Models, Animal; Drug Evaluation

2010
Simultaneous HPLC-UV analysis of rufinamide, zonisamide, lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in deproteinized plasma of patients with epilepsy.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2010, Feb-01, Volume: 878, Issue:3-4

    Topics: Anticonvulsants; Carbamazepine; Chromatography, High Pressure Liquid; Epilepsy; Felbamate; Humans; I

2010
Efficacy of felbamate in the treatment of intractable pediatric epilepsy.
    Pediatric neurology, 2010, Volume: 42, Issue:6

    Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Electroencephalography; Epilepsy; Felbamate; F

2010
P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats.
    Neuroscience letters, 2002, Jul-26, Volume: 327, Issue:3

    Topics: Animals; Anticonvulsants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barri

2002
Vagus nerve stimulation in a case of epilepsy with CSWSS: respiratory side effects during sleep.
    Epilepsia, 2002, Volume: 43, Issue:10

    Topics: Age Factors; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Child; Clobazam; Combined Modali

2002
Brain access and anticonvulsant efficacy of carbamazepine, lamotrigine, and felbamate in ABCC2/MRP2-deficient TR- rats.
    Epilepsia, 2003, Volume: 44, Issue:12

    Topics: Amygdala; Animals; Anticonvulsants; Biological Availability; Blood-Brain Barrier; Carbamazepine; Cer

2003
Preclinical profile of combinations of some second-generation antiepileptic drugs: an isobolographic analysis.
    Epilepsia, 2004, Volume: 45, Issue:8

    Topics: Animals; Anticonvulsants; Carbamazepine; Disease Models, Animal; Drug Evaluation, Preclinical; Drug

2004
Effects of anticonvulsants on soman-induced epileptiform activity in the guinea-pig in vitro hippocampus.
    European journal of pharmacology, 2005, Aug-22, Volume: 518, Issue:2-3

    Topics: Amines; Animals; Anticonvulsants; Carbamates; Carbamazepine; Chlormethiazole; Clozapine; Cyclohexane

2005
Simultaneous liquid chromatographic determination of lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in plasma of patients with epilepsy.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2005, Dec-15, Volume: 828, Issue:1-2

    Topics: Anticonvulsants; Carbamazepine; Chromatography, High Pressure Liquid; Dibenzazepines; Drug Monitorin

2005
Levetiracetam and felbamate interact both pharmacodynamically and pharmacokinetically: an isobolographic analysis in the mouse maximal electroshock model.
    Epilepsia, 2007, Volume: 48, Issue:4

    Topics: Animals; Anticonvulsants; Behavior, Animal; Brain; Chromatography, High Pressure Liquid; Disease Mod

2007
Lamotrigine as a possible cause of QRS prolongation in a patient with known seizure disorder.
    CJEM, 2006, Volume: 8, Issue:5

    Topics: Adult; Anticonvulsants; Electrocardiography; Epilepsy; Felbamate; Female; Humans; Lamotrigine; Pheny

2006
Evaluation of felbamate and other antiepileptic drug toxicity potential based on hepatic protein covalent binding and gene expression.
    Chemical research in toxicology, 2007, Volume: 20, Issue:4

    Topics: Animals; Anticonvulsants; Cells, Cultured; Epilepsy; Felbamate; Gene Expression Regulation; Humans;

2007
[Treatment of epilepsy with third-line antiepileptic drugs: felbamate, tiagabine, and sulthiame].
    Der Nervenarzt, 2007, Volume: 78, Issue:12

    Topics: Adult; Anticonvulsants; Epilepsy; Felbamate; Humans; Nipecotic Acids; Phenylcarbamates; Propylene Gl

2007
New antiepileptic drugs in pediatric epilepsy.
    Brain & development, 2008, Volume: 30, Issue:9

    Topics: Amines; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Cyclohexanecarboxylic Acids; Epilep

2008
New drugs for the treatment of epilepsy.
    The Nurse practitioner, 1995, Volume: 20, Issue:5

    Topics: Acetates; Amines; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Epilepsy; Felbamate; Gabape

1995
Felbamate in the treatment of acquired epileptic aphasia.
    Epilepsy research, 1995, Volume: 20, Issue:1

    Topics: Anticonvulsants; Aphasia; Child; Electroencephalography; Epilepsy; Felbamate; Humans; Language; Male

1995
Rectal administration of felbamate in a child with Lennox-Gastaut syndrome.
    Neurology, 1994, Volume: 44, Issue:10

    Topics: Administration, Rectal; Anticonvulsants; Child, Preschool; Epilepsy; Felbamate; Hemiplegia; Humans;

1994
Criteria for use of felbamate in adult, adolescent, and child inpatients and outpatients.
    American journal of hospital pharmacy, 1994, Jul-01, Volume: 51, Issue:13

    Topics: Administration, Oral; Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Epilepsies, Parti

1994
Novel antiepileptic drugs: nursing implications.
    The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses, 1993, Volume: 25, Issue:6

    Topics: Acetates; Amines; Aminocaproates; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Approval; Drug

1993
Science reporters hear wide range of recent data at 12th annual conference.
    JAMA, 1993, Nov-24, Volume: 270, Issue:20

    Topics: Acetates; Aged; AIDS Vaccines; American Medical Association; Amines; Animals; Anticonvulsants; beta-

1993
Alternative analyses for antiepileptic drug trials.
    Epilepsy research. Supplement, 1993, Volume: 10

    Topics: Anticonvulsants; Bias; Clinical Trials as Topic; Data Interpretation, Statistical; Dose-Response Rel

1993
From the Food and Drug Administration.
    JAMA, 1993, Oct-13, Volume: 270, Issue:14

    Topics: Adult; Anticonvulsants; Child; Drug Approval; Epilepsy; Felbamate; Heparin, Low-Molecular-Weight; Hu

1993
[Campaign against epilepsy].
    Medizinische Monatsschrift fur Pharmazeuten, 1993, Volume: 16, Issue:9

    Topics: Aminocaproates; Animals; Anticonvulsants; Epilepsy; Felbamate; Humans; Lamotrigine; Phenylcarbamates

1993
Effects of felbamate and other anticonvulsant drugs in two models of status epilepticus in the rat.
    Research communications in chemical pathology and pharmacology, 1993, Volume: 79, Issue:3

    Topics: Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Epilepsy; Felbam

1993
New antiepileptic medications.
    The Western journal of medicine, 1995, Volume: 163, Issue:5

    Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Dr

1995
Felbamate levels in patients with epilepsy.
    Epilepsia, 1996, Volume: 37, Issue:3

    Topics: Adolescent; Anorexia; Anticonvulsants; Child; Child, Preschool; Chromatography, High Pressure Liquid

1996
Felbamate-induced headache.
    Epilepsia, 1996, Volume: 37, Issue:5

    Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Anticonvulsants; Dose-Response Relationship, Drug

1996
Behavioral effects of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome).
    Psychological reports, 1995, Volume: 77, Issue:3 Pt 2

    Topics: Adolescent; Anticonvulsants; Brain Damage, Chronic; Child; Child Behavior Disorders; Child, Preschoo

1995
Weight loss in patients taking felbamate.
    Clinical neuropharmacology, 1995, Volume: 18, Issue:1

    Topics: Adolescent; Adult; Anticonvulsants; Body Weight; Child; Epilepsy; Felbamate; Humans; Middle Aged; Ph

1995
Anticonvulsant effect of felbamate in the pentylenetetrazole kindling model of epilepsy in the rat.
    Naunyn-Schmiedeberg's archives of pharmacology, 1996, Volume: 354, Issue:2

    Topics: Animals; Anticonvulsants; Epilepsy; Felbamate; Kindling, Neurologic; Male; Pentylenetetrazole; Pheny

1996
Gabapentin interaction with felbamate.
    Neurology, 1996, Volume: 47, Issue:4

    Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Interactions; Epilepsy;

1996
Psychiatric effects of felbamate.
    The Journal of neuropsychiatry and clinical neurosciences, 1997,Winter, Volume: 9, Issue:1

    Topics: Anticonvulsants; Epilepsy; Felbamate; Humans; Phenylcarbamates; Propylene Glycols; Substance Withdra

1997
New treatment options for epilepsy.
    Cleveland Clinic journal of medicine, 1997, Volume: 64, Issue:3

    Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Felbamate; Fructose; Gabap

1997
Felbamate: 1997 update.
    Epilepsia, 1997, Volume: 38, Issue:12

    Topics: Anemia, Aplastic; Anticonvulsants; Drug Approval; Epilepsy; Felbamate; Humans; Liver Failure; Phenyl

1997
Does antiepileptic therapy affect immune response?
    Journal of chemotherapy (Florence, Italy), 1998, Volume: 10, Issue:2

    Topics: Adolescent; Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Carbama

1998
Changes of the EEG paroxysmal pattern during felbamate therapy in Lennox-Gastaut syndrome: a case report.
    The International journal of neuroscience, 1998, Volume: 95, Issue:3-4

    Topics: Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Carbamazepine; Clobazam; Drug Therapy,

1998
Male infertility: possible association with valproate exposure.
    Epilepsia, 1999, Volume: 40, Issue:4

    Topics: Adult; Anticonvulsants; Drug Therapy, Combination; Epilepsy; Felbamate; Female; Humans; Infertility,

1999
Practice advisory: The use of felbamate in the treatment of patients with intractable epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society.
    Neurology, 1999, May-12, Volume: 52, Issue:8

    Topics: Anticonvulsants; Epilepsy; Felbamate; Humans; Phenylcarbamates; Propylene Glycols

1999
Quantification in patient urine samples of felbamate and three metabolites: acid carbamate and two mercapturic acids.
    Epilepsia, 1999, Volume: 40, Issue:6

    Topics: Acetylcysteine; Aldehydes; Animals; Anticonvulsants; Carbamates; Chromatography, High Pressure Liqui

1999
The use of felbamate in the treatment of patients with intractable epilepsy.
    Neurology, 2000, Mar-14, Volume: 54, Issue:5

    Topics: Anticonvulsants; Epilepsy; Felbamate; Humans; Phenylcarbamates; Propylene Glycols

2000
[Positive effect of falbamate therapy in a boy with refractory epilepsy].
    Neurologia i neurochirurgia polska, 2000, Volume: 34 Suppl 1

    Topics: Anticonvulsants; Child; Epilepsy; Felbamate; Humans; Phenylcarbamates; Propylene Glycols; Severity o

2000
[Preliminary assessment of felbamate effect on the cerebral bioelectrical activity in children with refractory epilepsy].
    Neurologia i neurochirurgia polska, 2000, Volume: 34 Suppl 1

    Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Electroencephalography; Epilepsy; Felbamate; F

2000
Re: Mazarati et al. "...clinically available [antiepileptic drug] with a moderate affinity for the glycine site of the N-methyl-D-aspartate (NMDA) receptor".
    Epilepsia, 2000, Volume: 41, Issue:7

    Topics: Anticonvulsants; Epilepsy; Felbamate; Glycine; Humans; N-Methylaspartate; Phenylcarbamates; Propylen

2000
[Clinical utilization of new anti-epileptic agents].
    Revue medicale de la Suisse romande, 2000, Volume: 120, Issue:9

    Topics: Acetates; Amines; Anemia, Aplastic; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Dru

2000
Felbamate urolithiasis.
    Epilepsia, 2001, Volume: 42, Issue:5

    Topics: Adolescent; Anticonvulsants; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epilepsy;

2001
The long-term use of felbamate in children with severe refractory epilepsy.
    Epilepsy research, 2001, Volume: 47, Issue:1-2

    Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Epilepsy; Felbamate; Female; Follow-Up

2001
Mechanisms of action of new antiepileptic drugs.
    Epilepsia, 1989, Volume: 30 Suppl 1

    Topics: Acetamides; Acetates; Amines; Aminocaproates; Aminopyridines; Anti-Anxiety Agents; Anticonvulsants;

1989